Integral Health Asset Management, LLC is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $1.9 billion in regulatory assets under management. Its private funds, of all types, hold $60.2 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +14.8% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +65.0% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $1.9 billionForm ADV Item 5.F
- Gross assets of private funds
- $60.2 millionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- 12Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 301987
- Latest Form ADV
- 03/26/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +17.9% | +14.8% |
| Q1 2026 | -2.6% | -4.6% |
| Q4 2025 | +15.2% | +2.4% |
| Q3 2025 | +26.3% | +7.8% |
| Q2 2025 | +7.1% | +10.4% |
| Q1 2025 | -5.0% | -4.5% |
| Q4 2024 | -8.5% | +2.1% |
| Q3 2024 | +6.1% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 96 share positions ($1,635,097,325) reported by Integral Health Asset Management, LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Revolution Medicines Inc7.97%
- Insmed Inc7.89%
- Edgewise Therapeutics Inc5.96%
- Cytokinetics Inc4.43%
- Merck & Co Inc4.00%
- Scholar Rock Hldg Corp3.71%
- Centene Corp Del2.85%
- Axsome Therapeutics Inc.2.82%
- Vera Therapeutics Inc1.97%
- Amgen Inc1.93%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Revolution Medicines Inc | $130,340,100 | 7.97% | 1,000,000 | -33.33% |
| Insmed Inc | $128,978,200 | 7.89% | 1,600,000 | Unchanged |
| Edgewise Therapeutics Inc | $97,440,000 | 5.96% | 2,400,000 | +20.00% |
| Cytokinetics Inc | $72,501,000 | 4.43% | 1,600,000 | Unchanged |
| Merck & Co Inc | $65,389,500 | 4.00% | 450,000 | +28.57% |
| Scholar Rock Hldg Corp | $60,641,600 | 3.71% | 1,255,000 | +67.33% |
| Centene Corp Del | $46,590,000 | 2.85% | 750,000 | +150.00% |
| Axsome Therapeutics Inc. | $46,097,500 | 2.82% | 250,000 | -16.67% |
| Vera Therapeutics Inc | $32,290,000 | 1.97% | 1,500,000 | -14.29% |
| Amgen Inc | $31,613,250 | 1.93% | 75,000 | New |
| Lifestance Health Group Inc | $31,278,000 | 1.91% | 2,600,000 | -13.33% |
| Regeneron Pharmaceuticals | $30,330,800 | 1.85% | 40,000 | Unchanged |
| Tenet Healthcare Corp | $23,000,400 | 1.41% | 90,000 | -45.45% |
| Biogen Inc | $22,588,000 | 1.38% | 100,000 | Unchanged |
| Tango Therapeutics Inc | $22,455,000 | 1.37% | 1,000,000 | Unchanged |
| Cardinal Health Inc | $22,250,000 | 1.36% | 100,000 | -66.67% |
| CVS Health Corp | $21,422,500 | 1.31% | 500,000 | -54.55% |
| Neurocrine Biosciences Inc | $21,276,000 | 1.30% | 150,000 | Unchanged |
| Vertex Pharmaceuticals Inc | $20,912,400 | 1.28% | 40,000 | Unchanged |
| Oric Pharmaceuticals Inc | $20,205,000 | 1.24% | 1,700,000 | -10.53% |
| Bridgebio Pharma Inc | $19,740,000 | 1.21% | 300,000 | +9.09% |
| Incyte Corp | $19,416,000 | 1.19% | 160,000 | New |
| Definium Therapeutics Inc | $19,030,000 | 1.16% | 500,000 | -9.09% |
| Brightspring Health Svcs Inc | $18,443,750 | 1.13% | 325,000 | -40.91% |
| Beone Medicines LTD | $18,297,000 | 1.12% | 50,000 | New |
| Roivant Sciences LTD | $18,285,000 | 1.12% | 2,000,000 | Unchanged |
| LB Pharmaceuticals Inc | $18,038,600 | 1.10% | 470,000 | +213.33% |
| Becton Dickinson & Co | $17,900,000 | 1.09% | 100,000 | New |
| Boston Scientific Corp | $17,460,000 | 1.07% | 400,000 | -55.56% |
| Edwards Lifesciences Corp | $17,264,000 | 1.06% | 200,000 | -68.00% |
| Erasca Inc | $16,565,800 | 1.01% | 1,130,000 | +13.00% |
| Alkermes PLC | $15,195,000 | 0.93% | 375,000 | +275.00% |
| Medtronic PLC | $15,100,750 | 0.92% | 175,000 | -12.50% |
| Glaukos Corp | $14,777,100 | 0.90% | 90,000 | -40.00% |
| Encompass Health Corp | $14,578,800 | 0.89% | 120,000 | New |
| Novartis AG | $14,257,000 | 0.87% | 100,000 | -50.00% |
| Absci Corporation | $14,001,000 | 0.86% | 1,300,000 | +62.50% |
| Quest Diagnostics Inc | $12,818,850 | 0.78% | 55,000 | -72.50% |
| Alto Neuroscience Inc | $12,765,000 | 0.78% | 500,000 | Unchanged |
| Madrigal Pharmaceuticals Inc | $12,599,000 | 0.77% | 25,000 | Unchanged |
| Bristol-myers Squibb Co | $12,480,000 | 0.76% | 200,000 | New |
| Uniqure NV | $12,080,000 | 0.74% | 500,000 | -44.44% |
| Rhythm Pharmaceuticals Inc | $11,901,875 | 0.73% | 250,000 | -54.55% |
| Teva Pharmaceutical Inds LTD | $11,880,000 | 0.73% | 300,000 | New |
| Travere Therapeutics Inc | $11,776,000 | 0.72% | 200,000 | -46.67% |
| Praxis Precision Medicines I | $11,649,200 | 0.71% | 40,000 | Unchanged |
| Livanova PLC | $11,475,000 | 0.70% | 150,000 | New |
| Waters Corp | $10,984,750 | 0.67% | 25,000 | -37.50% |
| Surrozen Inc | $10,458,500 | 0.64% | 325,000 | New |
| Inspire Med SYS Inc | $10,404,000 | 0.64% | 150,000 | +50.00% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 39 new positions, 32 sold out, 12 increased, 26 reduced and 19 unchanged.
Number of positions (a count, not dollars)
- New positions39
- Increased12
- Unchanged19
- Reduced26
- Sold out32
New positions
| Stock | Value | Shares |
|---|---|---|
| Amgen Inc | $31,613,250 | 75,000 |
| Incyte Corp | $19,416,000 | 160,000 |
| Beone Medicines LTD | $18,297,000 | 50,000 |
| Becton Dickinson & Co | $17,900,000 | 100,000 |
| Encompass Health Corp | $14,578,800 | 120,000 |
| Bristol-myers Squibb Co | $12,480,000 | 200,000 |
| Teva Pharmaceutical Inds LTD | $11,880,000 | 300,000 |
| Livanova PLC | $11,475,000 | 150,000 |
| Surrozen Inc | $10,458,500 | 325,000 |
| Tyra Biosciences Inc | $9,950,850 | 455,000 |
| Thermo Fisher Scientific Inc | $9,450,700 | 14,000 |
| Ovid Therapeutics Inc | $8,715,000 | 3,500,000 |
| Cooper Cos Inc | $8,479,500 | 150,000 |
| Climb Bio Inc | $8,029,000 | 700,000 |
| Attovia Therapeutics Inc | $7,713,000 | 450,000 |
| Alnylam Pharmaceuticals Inc | $7,402,200 | 30,000 |
| Faeth Therapeutics Inc | $7,137,600 | 240,000 |
| Guardant Health Inc | $7,134,400 | 40,000 |
| TG Therapeutics Inc | $6,972,500 | 125,000 |
| Ionis Pharmaceuticals Inc | $6,697,500 | 150,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Alignment Healthcare Inc | $47,620,000 | 2,000,000 |
| Abbott Laboratories | $36,296,000 | 400,000 |
| Unitedhealth Group Inc | $35,328,550 | 85,000 |
| Novo-nordisk A S | $28,764,000 | 600,000 |
| Lantheus Hldgs Inc | $21,078,600 | 190,000 |
| Elevance Health Inc Formerly | $19,336,500 | 50,000 |
| Eli Lilly & Co | $17,991,450 | 15,000 |
| Arrowhead Pharmaceuticals In | $16,302,000 | 200,000 |
| Envista Holdings Corporation | $15,810,000 | 600,000 |
| Livanova PLC | $14,801,400 | 180,000 |
| Forte Biosciences Inc | $14,343,750 | 675,000 |
| Xenon Pharmaceuticals Inc | $12,072,000 | 200,000 |
| Ascendis Pharma A/s | $12,002,400 | 45,000 |
| Acadia Healthcare Company In | $11,812,000 | 400,000 |
| Irhythm Holdings Inc | $10,705,500 | 90,000 |
| Integra Lifesciences Hldgs C | $9,878,000 | 550,000 |
| Ge Healthcare Technologies I | $9,601,500 | 150,000 |
| Bruker Corp | $9,027,000 | 150,000 |
| Cencora Inc | $8,489,400 | 30,000 |
| Bioage Labs Inc | $7,353,000 | 300,000 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Centene Corp Del | +450,000 | +150.00% | $46,590,000 | 750,000 |
| Scholar Rock Hldg Corp | +505,000 | +67.33% | $60,641,600 | 1,255,000 |
| Edgewise Therapeutics Inc | +400,000 | +20.00% | $97,440,000 | 2,400,000 |
| Merck & Co Inc | +100,000 | +28.57% | $65,389,500 | 450,000 |
| LB Pharmaceuticals Inc | +320,000 | +213.33% | $18,038,600 | 470,000 |
| Alkermes PLC | +275,000 | +275.00% | $15,195,000 | 375,000 |
| Absci Corporation | +500,000 | +62.50% | $14,001,000 | 1,300,000 |
| Inspire Med SYS Inc | +50,000 | +50.00% | $10,404,000 | 150,000 |
| Regenxbio Inc | +400,000 | +50.00% | $9,036,000 | 1,200,000 |
| Erasca Inc | +130,000 | +13.00% | $16,565,800 | 1,130,000 |
| Bridgebio Pharma Inc | +25,000 | +9.09% | $19,740,000 | 300,000 |
| Kardigan Inc | +25,000 | +12.50% | $3,318,750 | 225,000 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Revolution Medicines Inc | -500,000 | -33.33% | $130,340,100 | 1,000,000 |
| Cardinal Health Inc | -200,000 | -66.67% | $22,250,000 | 100,000 |
| Edwards Lifesciences Corp | -425,000 | -68.00% | $17,264,000 | 200,000 |
| Quest Diagnostics Inc | -145,000 | -72.50% | $12,818,850 | 55,000 |
| CVS Health Corp | -600,000 | -54.55% | $21,422,500 | 500,000 |
| Boston Scientific Corp | -500,000 | -55.56% | $17,460,000 | 400,000 |
| Tenet Healthcare Corp | -75,000 | -45.45% | $23,000,400 | 90,000 |
| Rhythm Pharmaceuticals Inc | -300,000 | -54.55% | $11,901,875 | 250,000 |
| Novartis AG | -100,000 | -50.00% | $14,257,000 | 100,000 |
| Brightspring Health Svcs Inc | -225,000 | -40.91% | $18,443,750 | 325,000 |
| Travere Therapeutics Inc | -175,000 | -46.67% | $11,776,000 | 200,000 |
| Glaukos Corp | -60,000 | -40.00% | $14,777,100 | 90,000 |
| Uniqure NV | -400,000 | -44.44% | $12,080,000 | 500,000 |
| Axsome Therapeutics Inc. | -50,000 | -16.67% | $46,097,500 | 250,000 |
| Waters Corp | -15,000 | -37.50% | $10,984,750 | 25,000 |
| Vera Therapeutics Inc | -250,000 | -14.29% | $32,290,000 | 1,500,000 |
| Biohaven LTD | -400,000 | -57.14% | $4,005,000 | 300,000 |
| Lifestance Health Group Inc | -400,000 | -13.33% | $31,278,000 | 2,600,000 |
| Beam Therapeutics Inc | -100,000 | -33.33% | $4,890,000 | 200,000 |
| Oric Pharmaceuticals Inc | -200,000 | -10.53% | $20,205,000 | 1,700,000 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (3)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (1)
As reported in the adviser's Form ADV filed Mar 27, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures